Sol-Gel acne cream reduces marks in late-stage studies, shares soar

Sol-Gel Technologies Ltd's shares more than tripled in value on Monday after the company said its lead acne drug candidate, Twyneo, met the main goal of reducing marks in two late-stage studies.

from Reuters: Health News https://ift.tt/2QA1wJB
via IFTTT